Interacciones de Levotiroxina y liotironina

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (etiqueta de Brimonidina y timolol, Advertencias y precauciones)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Clomiphene citrate tablets are contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or in the presence of an organic intracranial lesion such as pituitary tumor (see INDICATIONS AND USAGE). (etiqueta de Clomifeno, Contraindicaciones)

Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders). (etiqueta de Coriogonadotropina alfa, Contraindicaciones)

When concomitant administration of corticosteroids and levothyroxine is required, administration of corticosteroid should precede the initiation of levothyroxine therapy to avoid adrenal crisis. (etiqueta de Dexametasona, Advertencias y precauciones)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (etiqueta de Dorzolamida y timolol, Advertencias y precauciones)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. (etiqueta de Dulaglutida, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Reactions including anaphylaxis have been reported [see Adverse Reactions (6.2) ] High levels of FSH indicating primary gonadal failure Presence of uncontrolled non-gonadal endocrinopathies (e.g., thyroid, adrenal, or pituitary disorders) [see Indications and Usage (1.1 , 1.2 , 1.3) ] Hypersensitivity reactions to streptomycin or neomycin. (etiqueta de Folitropina, Contraindicaciones)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Do not take thyroid hormone replacement therapy within 2 hours of dosing with LANTHANUM CARBONATE. (etiqueta de Lantano, Interacciones medicamentosas)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice. (etiqueta de Liraglutida, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blockade which might precipitate a thyroid storm. (etiqueta de Nadolol, Advertencias)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-blockade which might precipitate a thyroid crisis. (etiqueta de Pindolol, Advertencias)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Avoid abrupt withdrawal of beta-blockade, which may precipitate a thyroid storm. (etiqueta de Propranolol, Advertencias y precauciones)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

WARNING: RISK OF THYROID C-CELL TUMORS • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etiqueta de Semaglutida, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Thyroid Abnormalities Avoid abrupt withdrawal of beta-blockade which might be followed by an exacerbation of symptoms of hyperthyroidism, including thyroid storm. (etiqueta de Sotalol, Advertencias y precauciones)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. (etiqueta de Timolol, Advertencias y precauciones)

WARNING: RISK OF THYROID C-CELL TUMORS In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. (etiqueta de Tirzepatida, Advertencia en recuadro)

People who have thyroid problems (hyperthyroidism) may have a higher chance of having a hypertensive crisis. (etiqueta de Tranilcipromina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (etiqueta de Levotiroxina y liotironina, Advertencia en recuadro)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Abrupt withdrawal of β-blockade may precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom acebutolol therapy is to be withdrawn should be monitored closely. (etiqueta de Acebutolol, Advertencias)

Levothyroxine The bioavailability of alendronate was slightly decreased when BINOSTO and levothyroxine were co-administered to healthy subjects [see Clinical Pharmacology (12.3) ] . (etiqueta de Alendronato, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Thyroid Abnormalities Nexterone inhibits peripheral conversion of throxine (T4) to triiodothyronine (T3) and may cause increased T3 levels, and increased levels of inactive reverse T3 (rT3) in clinically euthyroid patients. (etiqueta de Amiodarona, Advertencias y precauciones)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom TENORMIN therapy is to be withdrawn should be monitored closely. (etiqueta de Atenolol, Advertencias)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, patients suspected of developing thyrotoxicosis from whom atenolol and chlorthalidone therapy is to be withdrawn should be monitored closely. (etiqueta de Atenolol y clortalidona, Advertencias)

Monitor thyroid function before initiation of, and periodically throughout, treatment with INLYTA. (etiqueta de Axitinib, Advertencias y precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Abrupt withdrawal of beta-blockade might precipitate a thyroid storm; therefore, patients known or suspected of being thyrotoxic from whom betaxolol is to be withdrawn should be monitored closely (see Dosage and Administration: Cessation of therapy ). (etiqueta de Betaxolol, Advertencias)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Monitor and replace thyroid hormone if needed. (etiqueta de Bexaroteno, Advertencias y precauciones)

Laboratory Test Interactions Based on reports involving thiazides, bisoprolol fumarate and hydrochlorothiazide tablets may decrease serum levels of protein-bound iodine without signs of thyroid disturbance. (etiqueta de Bisoprolol e hidroclorotiazida, Precauciones)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Concomitant use with colesevelam hydrochloride may decrease the exposure of the following drugs: Drugs with a narrow therapeutic index (e.g., cyclosporine), phenytoin, thyroid hormone replacement therapy, warfarin, oral contraceptives containing ethinyl estradiol and norethindrone, olmesartan medoxomil, and sulfonylureas (glimepiride, glipizide, glyburide). (etiqueta de Colesevelam, Interacciones medicamentosas)

Drug Interactions Cholestyramine for Oral Suspension USP may delay or reduce the absorption of concomitant oral medication such as phenylbutazone, warfarin, thiazide diuretics (acidic), or propranolol (basic), as well as tetracycline, penicillin G, phenobarbital, thyroid and thyroxine preparations, estrogens and progestins, and digitalis. (etiqueta de Colestiramina, Interacciones medicamentosas)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Other metabolic events include a reduction in thyroid binding globulin and T4 with increased uptake of T3, but without disturbance of thyroid stimulating hormone or of free thyroxin index. (etiqueta de Danazol, Precauciones)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

In patients with thyroid disease or those taking thyroid medication, because of the possibility of cardiovascular toxicity, including arrhythmias. e. (etiqueta de Desipramina, Advertencias)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Use in Thyroid Disorders and Hypermetabolic States Hypothyroidism may reduce the requirements for digoxin. (etiqueta de Digoxina, Advertencias y precauciones)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Abnormal Thyroid Function Tests Dose-dependent decreases in serum T3 and T4 (free and total) values have been observed in patients taking APTIOM. (etiqueta de Eslicarbazepina, Advertencias y precauciones)

Abrupt withdrawal of beta blockade might precipitate a thyroid storm; therefore, monitor patients for signs of thyrotoxicosis when withdrawing beta blocking therapy. (etiqueta de Esmolol, Advertencias y precauciones)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Thyroid hormones High-doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels. (etiqueta de Furosemida, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

…recommended that appropriate references first be consulted to determine the usual precautions for the use of the other drug; e.g., when epinephrine is injected along with hyaluronidase, the precautions for the use of epinephrine in cardiovascular disease, thyroid disease, diabetes, digital nerve block, ischemia of the fingers and toes etc., should be observed. (etiqueta de Hialuronidasa, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

…levels of the drug; Patients with history of urinary retention, or history of narrow-angle glaucoma because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder because this drug has been shown to lower the seizure threshold;… (etiqueta de Imipramina, Advertencias)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Thyroid function should be monitored periodically. (etiqueta de Interferón beta-1a, Advertencias y precauciones)

Thyroid Function Abnormalities : Decreases in thyroid function may occur; perform tests where clinically indicated. (etiqueta de Lanreotida, Advertencias y precauciones)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

• Hypothyroidism and Hyperthyroidism: Monitor thyroid function regularly ( 5.7 ). (etiqueta de Litio, Advertencias y precauciones)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Thyroid Function Abnormalities MYCAPSSA suppresses the secretion of thyroid-stimulating hormone, which may result in hypothyroidism. (etiqueta de Octreotida, Advertencias y precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Drug Interactions and Decreased Vitamin Absorption ORLISTAT may interact with concomitant drugs including cyclosporine, levothyroxine, warfarin, amiodarone, antiepileptic drugs, and antiretroviral drugs [see Drug Interactions (7) ]. (etiqueta de Orlistat, Advertencias y precauciones)

Monitoring pituitary function (e.g., thyroid, adrenal, gonadal) prior to initiation of therapy with SIGNIFOR LAR, as well as periodically during treatment, as clinically appropriate, is recommended. (etiqueta de Pasireotida, Advertencias y precauciones)

Hypothyroidism : Monitor thyroid tests at baseline, during treatment and as clinically indicated and manage hypothyroidism as appropriate. (etiqueta de Pazopanib, Advertencias y precauciones)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Estrogen, Oral Contraceptives — Estrogens tend to increase serum thyroxine-binding globulin (TBg). (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Hypothyroidism Adults: Clinical trials with quetiapine demonstrated dose-related decreases in thyroid hormone levels. (etiqueta de Quetiapina, Advertencias y precauciones)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Substitute non-enzyme inducing therapies at least 2 weeks prior to initiation of irinotecan therapy Decrease irinotecan and active metabolite exposure Levothyroxine Decrease exposure Losartan Parent Decrease AUC by 30% Active metabolite (E3174) Decrease AUC by 40% Methadone In patients well-stabilized on methadone, concomitant administration of rifampin resulted… (etiqueta de Rifampicina, Interacciones medicamentosas)

…levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl rifapentine is mediated by an esterase enzyme. (etiqueta de Rifapentina, Interacciones medicamentosas)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

For oral medication where a reduction in the bioavailability of that medication would have a clinically significant effect on its safety or efficacy (e.g., cyclosporine, tacrolimus, levothyroxine), consider separation of the timing of the administration of the two drugs [see Clinical Pharmacology (12.3) ] . (etiqueta de Sevelámero, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Insulin or Oral Hypoglycemics — Initiating thyroid replacement therapy may cause increases in insulin or oral hypoglycemic requirements. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Hypothyroidism: Monitor thyroid function periodically as hypothyroidism may occur or worsen after initiation of somatropin. (etiqueta de Somatropina, Advertencias y precauciones)

• Impairment of Thyroid Stimulating Hormone Suppression (TSH) in DTC : Monitor TSH monthly and adjust thyroid replacement therapy in patients with thyroid cancer. (etiqueta de Sorafenib, Advertencias y precauciones)

• Thyroid Dysfunction : Monitor thyroid function at baseline, periodically during treatment, and as clinically indicated. (etiqueta de Sunitinib, Advertencias y precauciones)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (etiqueta de Tamoxifeno, Interacciones medicamentosas)

The therapy of myxedema coma requires simultaneous administration of glucocorticoids (See DOSAGE AND ADMINISTRATION). (etiqueta de Levotiroxina y liotironina, Precauciones)

Caution is advised in patients with history of urinary retention because of the drug's anticholinergic properties; hyperthyroid patients or those on thyroid medication because of the possibility of cardiovascular toxicity; patients with a history of seizure disorder, because this drug has been shown to lower the seizure threshold; patients receiving guanethidine… (etiqueta de Trimipramina, Advertencias)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Drug Interactions Oral Anticoagulants — Thyroid hormones appear to increase catabolism of vitamin K-dependent clotting factors. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (etiqueta de Ácido valproico, Advertencias y precauciones)

Hypocalcemia and Mineral Metabolism Preexisting hypocalcemia and disturbances of mineral metabolism (e.g., hypoparathyroidism, thyroid surgery, parathyroid surgery; malabsorption syndromes, excision of small intestine) must be effectively treated before initiating therapy with Reclast. (etiqueta de Ácido zoledrónico, Advertencias y precauciones)

Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram – see WARNINGS section. (etiqueta de Amitriptilina, Interacciones medicamentosas)

Abrupt withdrawal of beta-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (etiqueta de Bisoprolol, Advertencias)

Cytologic abnormalities characterized by giant, hyperchromatic nuclei have been reported in lymph nodes, pancreas, thyroid, adrenal glands, liver, and bone marrow. (etiqueta de Busulfano, Advertencias)

…dicumarol, dihydropyridine calcium channel blockers (e.g., felodipine), doxycycline, ethosuximide, everolimus, felbamate, glucocorticoids, haloperidol, imatinib, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, methsuxamide, mianserin, midazolam, mirtazapine, nefazodone, olanzapine, oral and other hormonal contraceptives, oxcarbazepine, paliperidone, phenytoin,… (etiqueta de Carbamazepina, Interacciones medicamentosas)

Abrupt withdrawal of β-blockade may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate thyroid storm. (etiqueta de Carvedilol, Advertencias y precauciones)

Secondary malignancies (urinary tract cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, and sarcomas) have been reported in patients treated with cyclophosphamide-containing regimens . (etiqueta de Ciclofosfamida, Advertencias y precauciones)

Losartan, glipizide and levothyroxine did not show any changes in exposure when co-administered with LOKELMA. (etiqueta de Ciclosilicato de sodio y zirconio, Interacciones medicamentosas)

Other Medications Used for the Management of Fanconi Syndrome PROCYSBI can be administered with other electrolyte and mineral replacements necessary for management of Fanconi syndrome, as well as vitamin D and thyroid hormone. (etiqueta de Cisteamina, Interacciones medicamentosas)

Cholestyramine or Colestipol - Cholestyramine or colestipol binds both T 4 and T 3 in the intestine, thus impairing absorption of these thyroid hormones. (etiqueta de Levotiroxina y liotironina, Interacciones medicamentosas)

Effect on Ketone and Thyroid Function Tests Valproate is partially eliminated in the urine as a keto-metabolite which may lead to a false interpretation of the urine ketone test. (etiqueta de Divalproato de sodio (valproato), Advertencias y precauciones)

Cases of myelodysplastic syndrome, acute leukemias, lymphomas, thyroid cancers, and sarcomas have occurred and may develop several years after chemotherapy has been discontinued. (etiqueta de Ifosfamida, Advertencias y precauciones)

Hypothyroidism has been reported in thyroidectomy patients undergoing levothyroxine replacement. (etiqueta de Imatinib, Advertencias y precauciones)

Thyroid Disorders Both hypothyroidism and hyperthyroidism have been reported [see Adverse Reactions (6.2) ] . (etiqueta de Lenalidomida, Advertencias y precauciones)

Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (etiqueta de Metiltestosterona, Precauciones)

Thyrotoxicosis: Abrupt withdrawal in patients with thyrotoxicosis might precipitate a thyroid storm. (etiqueta de Metoprolol, Advertencias y precauciones)

Abrupt withdrawal in thyrotoxicosis might precipitate a thyroid storm. (etiqueta de Metoprolol e hidroclorotiazida, Advertencias y precauciones)

EMROSI may induce hyperpigmentation in many organs, including nails, bone, skin, eyes, thyroid, visceral tissue, oral cavity (teeth, mucosa, alveolar bone), sclerae and heart valves. (etiqueta de Minociclina, Advertencias y precauciones)

In cases of cognitive dysfunction, thyroid function should be evaluated as mitotane may induce hypothyroidism. (etiqueta de Mitotano, Advertencias y precauciones)

Abrupt withdrawal of β-blockers may be followed by an exacerbation of the symptoms of hyperthyroidism or may precipitate a thyroid storm. (etiqueta de Nebivolol, Advertencias y precauciones)

Great care is required if Pamelor is given to hyperthyroid patients or to those receiving thyroid medication, since cardiac arrhythmias may develop. (etiqueta de Nortriptilina, Advertencias)

…performed, the following concomitant drugs were used in at least 10% of patients in either or both Sjogren's efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone. (etiqueta de Pilocarpina, Interacciones medicamentosas)

On rare occasions, hyperthyroid patients or those receiving thyroid medication may develop arrhythmias when this drug is given. (etiqueta de Protriptilina, Advertencias)

Free thyroid hormone concentrations remain unchanged, however, and there is no clinical evidence of thyroid dysfunction. (etiqueta de Testosterona, Advertencias y precauciones)

Warnings Potassium iodide can cause fetal harm, abnormal thyroid function, and goiter when administered to a pregnant woman. (etiqueta de Yoduro de potasio, Advertencias)

Thyroid-stimulating hormone, total thyroxine, and thyrotropin-releasing hormone response are not affected. (etiqueta de Fenoprofeno, Interacciones medicamentosas)

…adjustment is needed when SINGULAIR is co-administered with theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, gemfibrozil, itraconazole, thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, decongestants, and Cytochrome P450 (CYP) enzyme inducers [see Clinical Pharmacology (12.3)… (etiqueta de Montelukast, Interacciones medicamentosas)